US Patent Issued to AstraZeneca on Nov. 18 for "Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same" (Swedish Inventor)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,472,194, issued on Nov. 18, was assigned to AstraZeneca AB (Sodertalje, Sweden).

"Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same" was invented by Anna Maria Langkilde (Gothenburg, Sweden).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed."

The patent was filed on Oct. 19, 2023, under Application No. 18/381,960.

*For further information, including images, charts and t...